2022-06-26-世界卫生组织-C-19_Vaccine_price_data_from_public_source_and_as_reported_by_countries_to_WHO_13页_586kb

Summary of COVID-19 Vaccine Price Data

This document analyzes COVID-19 vaccine prices based on the MI4A purchase database, incorporating data from WHO/UNICEF eJRF reports and public sources up to March 31, 2022. The data covers all vaccine purchases reported by countries and categorizes prices by income group (LICs, LMICs, UMICs, HICs) and procurement method (COVAX, bilateral, multilateral).

Key findings:

• Overall Price Patterns: Prices vary widely by income group and vaccine source. Lower-income countries typically pay lower prices, but some vaccines show higher costs in high-income regions due to negotiation or procurement method.
• Income Group Comparison:
  • Low-income countries (LICs) often have lower median prices, e.g., AstraZeneca costs around $4.00, while higher-income countries may pay up to $50.
  • Middle-income countries (UMICs and LMICs) show more price diversity; LMICs sometimes match low-income prices for certain vaccines.
  • High-income countries (HICs) frequently report higher prices but also lower weighted averages for some vaccines like Pfizer or SII Covishield.
• Procurement Method Analysis: COVAX tends to offer lower median prices compared to bilateral agreements. Multilateral deals show high variability, with some vaccines priced significantly higher. Bilateral agreements often reflect national negotiations, leading to diverse pricing.
• Vaccine-Specific Insights:
  • AstraZeneca and Pfizer report stable prices (e.g., $4-$7 for AstraZeneca across groups), but Covishield (SII) varies widely.
  • Emerging vaccines like Moderna and Nanogen show higher prices, especially in upper-middle and high-income groups.
  • Exceptions exist, such as Bharat Covaxin, which has low prices in some contexts.

For detailed tables and full methodology, refer to the MI4A database: https://www.who.int/teams/immunization-vaccines-and-biologicals/vaccine-access/mi4a/mi4a-vaccine-purchase-data.